- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05864014
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
May 17, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
192
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qian Tang
- Phone Number: +86 177 2128 6353
- Email: Qian.tang@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Men and women, 18-75 years of age;
- Participant with a histologically or cytologically confirmed solid tumor receiving treatment with chemotherapeutic agents;
- Participant experienced thrombocytopenia and chemotherapy delay;
- ECOG performance status 0-1;
- Adequate Liver function; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN for participants without liver metastases or 5.0 x ULN for participant with liver metastases);
- Adequate renal function; serum creatinine < 1.5 x ULN or eGFR≤60 ml/min(Cockcroft-Gault)
Exclusion Criteria:
- Participant has any history of hematologic diseases other than chemotherapy-induced thrombocytopenia;
- Participant has serious bleeding symptoms;
- History of allergy to the study drug;
- Participant with HIV;
- Pregnant or lactating women;
- Participant has received any experimental therapy within 4 weeks prior to screening
- Other conditions that may affect participant's safety or trial evaluations per investigator's discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: Hetrombopag
|
Hetrombopag
|
Experimental: Hetrombopag plus Placebo
|
Hetrombopag plus Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of treatment responders.
Time Frame: Randomization up to 80 days
|
Randomization up to 80 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration from the commencement of treatment to a platelet count ≥100×109/L;
Time Frame: Randomization up to 30 days
|
Randomization up to 30 days
|
Proportion of subjects who could complete chemotherapy without dose modification and rescue therapy and;
Time Frame: Randomization up to 160 days
|
Randomization up to 160 days
|
Proportion of subjects without serious bleeding events;
Time Frame: Randomization up to 190 days
|
Randomization up to 190 days
|
Number of adverse events (AEs)/serious adverse events (SAEs)
Time Frame: Randomization up to 190 days
|
Randomization up to 190 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2023
Primary Completion (Anticipated)
September 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
May 9, 2023
First Submitted That Met QC Criteria
May 17, 2023
First Posted (Actual)
May 18, 2023
Study Record Updates
Last Update Posted (Actual)
May 18, 2023
Last Update Submitted That Met QC Criteria
May 17, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR8735-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-Induced Thrombocytopenia
-
Sobi, Inc.CompletedChemotherapy-induced ThrombocytopeniaUnited States, China, Hungary, Poland, Russian Federation, Serbia, Ukraine
-
Beijing Northland Biotech. Co., Ltd.CompletedChemotherapy-induced ThrombocytopeniaChina
-
BioMAS LtdTerminatedChemotherapy Induced ThrombocytopeniaIsrael
-
Qilu Pharmaceutical Co., Ltd.RecruitingChemotherapy-induced ThrombocytopeniaChina
-
Qilu Pharmaceutical Co., Ltd.CompletedChemotherapy-induced ThrombocytopeniaChina
-
Napolitano MariasantaRegione SiciliaTerminatedThrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy InducedItaly
-
Jiangsu HengRui Medicine Co., Ltd.Withdrawn
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingChemotherapy-Induced ThrombocytopeniaChina
-
Ono Pharma USA IncTerminatedChemotherapy-Induced ThrombocytopeniaUnited States, Korea, Republic of, Russian Federation
-
Institute of Hematology & Blood Diseases HospitalHenan Cancer Hospital; Tianjin Medical University Cancer Institute and Hospital and other collaboratorsRecruitingChemotherapy-induced Thrombocytopenia | HerombopagChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States